Seeing Machines forms eye disease master pact with Australian National University:
This article was originally published in Clinica
Executive Summary
Canberra, Australia-based Seeing Machines has signed a master development and commercialisation deal with the Australian National University (ANU) to develop diagnostics for eye diseases, such as glaucoma. Under the agreement, computer vision systems maker Seeing Machines will provide the university, also based in Canberra, with equipment, software and know-how, including non-commercialised proprietary technologies. In return, the company has first rights to exclusively commercialise any new IP developed under the pact. The company and the ANU have already teamed up on the development of the company's TrueField Analyzer, for helping doctors diagnose and manage a range of eye diseases, including glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy. The device has yet to reach the market.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.